MUC1对胰腺导管腺癌诊断效能的Meta分析  

Diagnostic performance of MUC1 for pancreatic ductal adenocarcinoma: a meta-analysis

作　　者：江志敏[1] 杨琼[1] 陈邓林[1] 毕卓菲[1] 林显敢[1] 刘天浩[1] 李志花[1] 谢德荣[1] 

机构地区：[1]中山大学附属第二医院肿瘤科,广东省广州市510120

出　　处：《世界华人消化杂志》2008年第11期1248-1253,共6页World Chinese Journal of Digestology

基　　金：广东省科技计划项目;No.2007B031516014~~

摘　　要：目的:系统评价MUC1对胰腺导管腺癌的诊断价值.方法:通过检索获得公开发表的研究免疫组化技术检测MUC1诊断胰腺导管腺癌的文献,筛选文献,评价文献质量并提取纳入文献中有关准确度的数据,采用MetaDiSc1.4软件检验研究间的异质性、对诊断准确度指标进行Meta分析并进行综合受试者工作特征分析.结果:17篇文献符合纳入标准,涉及研究对象1363例.异质性检验无阈值效应,但存在其它异质性.Meta分析的结果显示MUC1诊断胰腺癌的总敏感度0.83(95%CI0.81-0.86)、总特异度0.63(95%CI0.59-0.66)、总诊断优势比20.44(95%CI9.53-43.85).综合受试者工作特征曲线下面积0.8879,Q*指数为0.8185.结论:MUC1检测对胰腺癌的诊断准确度中等,可作为胰腺癌筛查的检查方法.AIM： To systematically assess the diagnostic performance of MUC1 for pancreatic ductal adenocarcinoma. METHODS： A comprehensive search was performed to retrieve relevant studies on detecting immunohistochemical expression of MUC1 in the diagnosis of pancreatic ductal adenocarcinoma. Data on accuracy of included studies were extracted for further heterogeneity exploring, statistical pooling and SROC （summary receiver operating characteristics） analyzing using the MetaDiSc1.4 software. RESULTS： Seventeen studies were selected, with 1363 patients involved. The heterogeneity （except for threshold effect） was found in thesestudies. The pooled accuracy indicators like sensitivity, specificity, and diagnostic odds ratio （DOR） were 0.83 （95% CI： 0.81-0.86）, 0.63 （95% CI： 0.59-0.66）, and 20.44 （95% CI： 9.53-43.85）, respectively. The area under of SROC curve was 0.8879 and the Q index was 0.8185. CONCLUSION： The meta-analysis indicates a moderate diagnostic accuracy of MUC1 for pancreatic ductal adenocarcinoma. It can be an optional method in the examination of pancreatic cancer.

关 键 词：胰腺导管腺癌 MUC1 免疫组织化学 META分析 

分 类 号：R735.9[医药卫生—肿瘤] R195.1[医药卫生—临床医学]